Letter to the editor

Therapeutic potential of berberine in cancer treatment: Current update

Safwan Hazaa1, Yachana Mishra2[*], Vijay Mishra1

1School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab)-144411, India

2School of Bioengineering and Biosciences, Lovely Professional University, Phagwara (Punjab)-144411, India

EXCLI J 2026;25:Doc991

 

Berberine (BBR) is a benzyl tetra isoquinoline alkaloid bioactive agent (Supplementary Figure 1excli2026-9530_supplementary_information.pdf), specifically 2,3-methylenedioxy-9,10-dimethoxy protoberberine chloride (C20H18NO4), with a calculated molecular weight of 336.36 g/mol. This compound is well-documented as a phytochemical constituent extracted and isolated from diverse botanical sources, such as Coptis rhizomes, Pellodendron chenins, and Berberis vulgaris (Rauf et al., 2021[2]). BBR exhibits noteworthy pharmacological activity against various diseases, inclusive of highly antidiabetic effects (Liang et al., 2019[1]), anti-inflammatory properties, anti-tumor activity, regulation of blood lipid and glucose levels, as well as potential roles in treatment of osteoporosis and osteoarthritis (Zhang et al., 2021[3]). Moreover, numerous studies have investigated the effects of berberine on various cancers, elucidating its underlying mechanisms of action. These investigations have led to a substantial body of literature encompassing diverse anticancer effects. Therefore, this letter aims to comprehensively address the therapeutic potential of berberine in the treatment of different types of cancer (Supplementary Table 1excli2026-9530_supplementary_information.pdf).

Declaration

Funding

None.

Conflict of interest

The authors declare no conflict of interest.

Artificial Intelligence (AI) - assisted technology

During the preparation of this letter, the authors used the Grammarly tool solely for language improvement, sentence structure enhancement, and grammar checking. The authors did not use AI tools for data analysis, interpretation, or the generation of scientific conclusions. After using this tool, the authors thoroughly reviewed, edited, and validated all content and take full responsibility for the accuracy, integrity, and scientific validity of the work. The authors assume full responsibility for the accuracy, originality, and scientific integrity of the final content of the published letter.

 

References

1. Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: A systematic literature review and a meta-analysis. Endocr J. 2019;66:51–63. doi: 10.1507/endocrj.EJ18-0109
2. Rauf A, Abu-Izneid T, Khalil AA, Imran M, Shah ZA, Bin Emran T, et al. Berberine as a potential anticancer agent: A comprehensive review. Molecules. 2021;26:7368. doi: 10.3390/molecules26237368
3. Zhang Y, Ma J, Zhang W. Berberine for bone regeneration: Therapeutic potential and molecular mechanisms. J Ethnopharmacol. 2021;277:114249. doi: 10.1016/j.jep.2021.114249
 
 

File-Attachments

  1. excli2026-9530_supplementary_information.pdf (387,97 KB)
    Supplementary information
 
 
 

[*] Corresponding Author:

Dr. Yachana Mishra, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara (Punjab)-144411, India, eMail: yachanamishra@gmail.com